Join BIOCYTOGEN at Gene-ius Break – Oct 23rd Maryland Biotech/ Biopharma Forum
We’re excited to share that BIOCYTOGEN will be hosting the Gene-ius Break in Maryland on October 23rd! This special event will gather leading scientists from both basic and clinical research to discuss key topics such as early-stage drug discovery and FDA approval processes. It’s the perfect opportunity to connect with industry experts, gain valuable insights, and share ideas that are shaping the future of biotech. And of course, enjoy complimentary food and drinks while expanding your professional network in a relaxed and engaging atmosphere.
What is the Gene-ius Break Forum?
The Gene-ius Break Forum gathers over 60 industry leaders, researchers, investors, and entrepreneurs from the global biotech sector. Featuring a dynamic lineup of esteemed speakers and panelists, the event includes engaging presentations on cutting-edge topics in biotechnology. Attendees can participate in interactive panel discussions, allowing for meaningful conversations with thought leaders. Enjoy complimentary food and drinks while networking and exploring the latest trends and innovations in the field. Whether you’re an experienced professional or new to the industry, this forum offers valuable insights to help you stay ahead in the rapidly evolving biotech landscape.
Event Overview
Date: October 23rd · 4:30pm – 8pm EST
Venue: Greencourt Innovation Center. 12358 Parklawn Dr. Rockville, MD 20852
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
Join us for an evening of forward-thinking discussions, expert insights, and valuable connections. We can’t wait to see you there!